Page last updated: 2024-12-08

ginsenoside rg1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators
FloraRankFlora DefinitionFamilyFamily Definition
PanaxgenusAn araliaceous genus of plants that contains a number of pharmacologically active agents used as stimulants, sedatives, and tonics, especially in traditional medicine. Sometimes confused with Siberian ginseng (ELEUTHEROCOCCUS).[MeSH]AraliaceaeThe ginseng plant family of the order Apiales, subclass Rosidae, class Magnoliopsida. Leaves are generally alternate, large, and compound. Flowers are five-parted and arranged in compound flat-topped umbels. The fruit is a berry or (rarely) a drupe (a one-seeded fruit). It is well known for plant preparations used as adaptogens (immune support and anti-fatigue).[MeSH]
Panax japonicusspecies[no description available]AraliaceaeThe ginseng plant family of the order Apiales, subclass Rosidae, class Magnoliopsida. Leaves are generally alternate, large, and compound. Flowers are five-parted and arranged in compound flat-topped umbels. The fruit is a berry or (rarely) a drupe (a one-seeded fruit). It is well known for plant preparations used as adaptogens (immune support and anti-fatigue).[MeSH]
Panax ginsengspecies[no description available]AraliaceaeThe ginseng plant family of the order Apiales, subclass Rosidae, class Magnoliopsida. Leaves are generally alternate, large, and compound. Flowers are five-parted and arranged in compound flat-topped umbels. The fruit is a berry or (rarely) a drupe (a one-seeded fruit). It is well known for plant preparations used as adaptogens (immune support and anti-fatigue).[MeSH]

Cross-References

ID SourceID
PubMed CID441923
CHEMBL ID501637
CHEBI ID67987
SCHEMBL ID19875635
MeSH IDM0107649

Synonyms (59)

Synonym
BIDD:ER0075
panaxoside a
panaxoside rg1
einecs 244-989-9
ginsenoside a2
beta-d-glucopyranoside, (3beta,6alpha,12beta)-3,12-dihydroxydammar-24-ene-6,20-diyl bis-
(3beta,6alpha,12beta)-3,12-dihydroxydammar-24-ene-6,20-diyl bis-beta-d-glucopyranoside
sanchinoside rg1
(3beta,6alpha,12beta)-3,12-dihydroxydammar-24-ene-6,20-diylbis(beta-d-glucopyranoside)
ginsenoside g1
beta-d-glucopyranoside, (3beta,6alpha,12beta)-3,12-dihydroxy dammar-24-ene-6,20-diylbis-
(6)-beta-d-glucopyranosyl-(20)-beta-d-glucopyranosyl-20s-protopanaxatriol
ginsenoside-rg1
RG1 ,
ginsenoside rg1 ,
(20s)-ginsenoside rg1
sanchinoside c1
22427-39-0
C08946
DB06750
CHEMBL501637 ,
chebi:67987 ,
A816192
(3b,6a,12b)-3,12-dihydroxydammar-24-ene-6,20- diylbis(beta-d-glucopyranoside)
unii-pj788634qy
pj788634qy ,
(3beta,alpha,12beta)-20-(beta-d-glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl beta-d-glucopyranoside
S3923
CS-3832
Q-100285
SCHEMBL19875635
(3.beta.,6.alpha.,12.beta.)-3,12-dihydroxydammar-24-ene-6,20- diylbis(.beta.-d-glucopyranoside)
ginsenoside rg1 [usp-rs]
ginsenoside rg1 (constituent of american ginseng, asian ginseng, and tienchi ginseng) [dsc]
.beta.-d-glucopyranoside, (3.beta.,6.alpha.,12.beta.)-3,12- dihydroxy dammar-24-ene-6,20-diylbis-
.beta.-d-glucopyranoside, (3.beta.,6.alpha.,12.beta.)-3,12-dihydroxydammar-24-ene-6,20-diyl bis-
(6)-.beta.-d-glucopyranosyl-(20)-.beta.-d-glucopyranosyl-20s- protopanaxatriol
ginsenoside rg1 [who-dd]
HY-N0045
mfcd00210293
ginsenoside rg1, analytical standard
ginsenoside rg1, primary pharmaceutical reference standard
ginsenoside rg1, united states pharmacopeia (usp) reference standard
YURJSTAIMNSZAE-HHNZYBFYSA-N
(2r,3r,4s,5s,6r)-2-(((3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-((s)-6-methyl-2-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)hept-5-en-2-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-
AKOS037514672
7-hydroxy-2-oxo-2h-chromene-3-carboxylicacidamide
BS-16671
6-(hexopyranosyloxy)-3,12-dihydroxydammar-24-en-20-yl hexopyranoside
DTXSID70945111
Q2276594
ginsenosiderg1
HMS3885M12
CCG-270492
panaxoside a;panaxoside rg1
EX-A6784
ginsenoside rg1 (constituent of american ginseng, asian ginseng, and tienchi ginseng)
ginsenoside rg1 (usp-rs)
G0533

Research Excerpts

Overview

Ginsenoside Rg1 is a saponin isolated and purified from ginseng that exerts protective effects on the liver in some liver injury models. It has potential as an effective medication for protecting against TCDD-associated liver injury.

ExcerptReferenceRelevance
"Ginsenoside Rg1 is a saponin isolated and purified from ginseng that exerts protective effects on the liver in some liver injury models."( Ginsenoside Rg1 protects mice against 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced liver injury by inhibiting CYP1A1 through the aryl hydrocarbon receptor.
Chen, TF; Gao, Y; Gao, YH; Huo, W; Li, H; Song, L; Ye, ZG; Zhang, GP, 2022
)
2.89
"Ginsenoside Rg1 is a potent partial AhR agonist that has potential as an effective medication for protecting against TCDD-associated liver injury."( Ginsenoside Rg1 protects mice against 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced liver injury by inhibiting CYP1A1 through the aryl hydrocarbon receptor.
Chen, TF; Gao, Y; Gao, YH; Huo, W; Li, H; Song, L; Ye, ZG; Zhang, GP, 2022
)
3.61
"Ginsenoside Rg1 is an important active substance isolated from the root of ginseng. "( Revealing the Therapeutic Targets and Mechanism of Ginsenoside Rg1 for Liver Damage Related to Anti-Oxidative Stress Using Proteomic Analysis.
Hou, J; Ma, R; Wang, Y; Zhu, S, 2022
)
2.42
"Ginsenoside Rg1 is an effective drug that promotes angiogenesis."( Ginsenoside Rg1 Nanoparticles Induce Demethylation of H3K27me3 in VEGF-A and Jagged 1 Promoter Regions to Activate Angiogenesis After Ischemic Stroke.
Cai, H; Lu, L; Shang, W; Shen, J; Wang, D; Xu, Z; Yang, F; Zhao, X; Zhao, Z, 2022
)
2.89
"Ginsenoside Rg1 (Rg1) is a bioactive compound with pharmacological potential for cardiac protection."( Ginsenoside Rg1 protects cardiac mitochondrial function via targeting GSTP1 to block S-glutathionylation of optic atrophy 1.
Li, P; Li, Y; Yan, C; Yang, H; Yao, P; Zhu, H, 2023
)
3.07
"Ginsenoside Rg1 is a major active ingredient in processed ginseng, which elicits proven biological and pharmacological effects."( Ginsenoside Rg1 protects mice against streptozotocin-induced type 1 diabetic by modulating the NLRP3 and Keap1/Nrf2/HO-1 pathways.
Chen, N; Chu, S; Gao, Y; Li, J; Li, L; Zhang, L; Zhang, Z, 2020
)
2.72
"Ginsenoside Rg1 is an active ingredient extracted from the roots of ginsenoside, and an α-naphthylisothiocyanate (ANIT)-induced rat model of intrahepatic cholestasis was used to investigate the protective effect of Rg1 on cholestasis. "( Ginsenoside Rg1 alleviates ANIT-induced intrahepatic cholestasis in rats via activating farnesoid X receptor and regulating transporters and metabolic enzymes.
Du, R; Gao, Y; Huang, W; Li, J; Ren, H; Xiao, Q; Zhang, S; Zhao, J; Zhu, Y, 2020
)
3.44
"Ginsenoside Rg1 is a monomer component extracted from Panax ginseng."( Ginsenoside Rg1 ameliorates reproductive function injury in C57BL/6J mice induced by di-N-butyl-phthalate.
Li, H; Li, Z; Qian, H; Qu, Z; Sun, X; Xu, X; Zhao, X, 2021
)
2.79
"Ginsenoside Rg1 is a major active constituent of Panax ginseng and possesses anti-inflammatory effects. "( Ginsenoside Rg1 attenuates the inflammatory response in DSS-induced mice colitis.
Shi, F; Wang, H; Wang, T; Zhu, G, 2017
)
3.34
"Ginsenoside Rg1 (Rg1) is a steroidal saponin found in ginseng."( Ginsenoside Rg1 protects against neuronal degeneration induced by chronic dexamethasone treatment by inhibiting NLRP-1 inflammasomes in mice.
Hu, W; Huang, D; Huang, R; Li, W; Yin, Y; Zhang, B; Zhang, J; Zhang, Y, 2017
)
2.62
"Ginsenoside Rg1 (G‑Rg1) is an active ingredient of Panax ginseng, which has previously been reported to attenuate alcohol‑induced hepatic damage; however, the underlying mechanisms remain largely unknown. "( Ginsenoside Rg1 inhibits inflammatory responses via modulation of the nuclear factor‑κB pathway and inhibition of inflammasome activation in alcoholic hepatitis.
Chen, Y; Huang, W; Li, J; Liu, S; Luo, H; Yang, C; Zhang, S; Zhao, L, 2018
)
3.37
"Ginsenoside Rg1 is an extract of Panax ginseng in traditional Chinese medicine."( Ginsenoside Rg1 ameliorates testicular senescence changes in D‑gal‑induced aging mice via anti‑inflammatory and antioxidative mechanisms.
Chen, LB; Chen, XB; Li, J; Liu, Y; Qiu, Z; Wang, L; Wang, YP; Wang, ZL, 2018
)
2.64
"Ginsenoside Rg1 (Rg1) is a steroidal saponin found in ginseng."( Ginsenoside Rg1 protects against H2O2‑induced neuronal damage due to inhibition of the NLRP1 inflammasome signalling pathway in hippocampal neurons in vitro.
Chen, YL; Huang, DK; Li, WZ; Shen, XY; Sun, LL; Xu, TZ; Zhang, BQ, 2019
)
2.68
"Ginsenoside Rg1 (GS Rg1) is a glycosylated triterpenoid saponin extracted from Panax ginseng. "( Ginsenoside Rg1 attenuates protein aggregation and inflammatory response following cerebral ischemia and reperfusion injury.
Bai, Y; Chen, Y; Jiang, H; Jin, R; Xu, H; Zhao, Y; Zheng, T, 2019
)
3.4
"Ginsenoside Rg1 (Rg1) is an active components in Panax ginseng, a famous traditional Chinese medicines recorded in Compendium of Materia Medica."( Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis.
Dou, Y; Hsieh, Y; Liu, Q; Liu, Y; Lou, Y; Tao, R; Yan, J; Zhu, D, 2013
)
1.34
"Ginsenoside Rg1 (Rg1) is a steroidal saponin abundantly contained in ginseng."( Protective effects of ginsenoside Rg1 on chronic restraint stress induced learning and memory impairments in male mice.
Hu, W; Kan, H; Li, W; Wang, M; Wang, Y; Wu, W; Yin, Y, 2014
)
1.44
"Ginsenoside Rg1 is an active ingredient of Panax ginseng in traditional Chinese medicine, which exerts anti-oxidative and anti-aging effects."( Ginsenoside Rg1 prevents cognitive impairment and hippocampus senescence in a rat model of D-galactose-induced aging.
Chen, J; Li, C; Li, T; Liu, J; Mu, X; Wang, Y; Xu, C; Zeng, J; Zhang, M; Zhu, J, 2014
)
2.57
"Ginsenoside Rg1 is a natural product extracted from Panax ginseng C.A. "( The study of mechanisms of protective effect of Rg1 against arthritis by inhibiting osteoclast differentiation and maturation in CIA mice.
Fan, W; Gu, Y; Yin, G, 2014
)
1.85
"Ginsenoside Rg1 (Rg1) is a major bioactive ingredient in Panax ginseng that has low toxicity and has been shown to have neuroprotective effects. "( Neuroprotective effects of ginsenoside Rg1 through the Wnt/β-catenin signaling pathway in both in vivo and in vitro models of Parkinson's disease.
Gong, X; Li, S; Liang, Z; Wang, X; Zhang, X; Zhao, J; Zhou, T; Zu, G, 2016
)
2.17
"Ginsenoside Rg1 (Rg1) is a multipotent triterpene saponin extracted from ginseng, and has been proven to act as a nootropic agent against various types of neurological damage. "( Ginsenoside Rg1 exerts a protective effect against Aβ₂₅₋₃₅-induced toxicity in primary cultured rat cortical neurons through the NF-κB/NO pathway.
Lou, Y; Wu, J; Yang, H; Zhang, X; Zhao, Q, 2016
)
3.32
"Ginsenoside Rg1 is a valuable bioactive molecule but its high polarity and low concentration in complex mixtures makes it a challenge to separate Ginsenoside Rg1 from other saponins with similar structures, resulting in low extraction efficiency. "( Innovative method for the enrichment of high-polarity bioactive molecules present at low concentrations in complex matrices.
Gu, YL; He, J; Huang, H; Li, KQ; Liu, QS; Yin, XY; Zhou, WB, 2017
)
1.9
"The ginsenoside Rg1 is a novel natural antioxidant isolated from the medicinal plant Panax ginseng C.A."( Ginsenoside Rg1 attenuates ultraviolet B-induced glucocortisides resistance in keratinocytes via Nrf2/HDAC2 signalling.
Cheng, B; Du, J; Li, J; Ling, C; Liu, D; Wang, Y; Wu, J; Yin, Z; Zhang, D; Zhang, Y, 2016
)
2.36
"Ginsenoside Rg1 (Rg1) is a pharmaceutically active component of ginseng, and is neuroprotective as reported. "( Ginsenoside Rg1 attenuates beta-amyloid-induced apoptosis in mutant PS1 M146L cells.
Guan, Y; Jia, J; Liang, P; Wei, C, 2008
)
3.23
"Ginsenoside Rg1 is a major active ingredient of Panax notoginseng radix which has demonstrated a number of pharmacological actions including a cardioprotective effect in vivo. "( Ginsenoside Rg1 protects rat cardiomyocyte from hypoxia/reoxygenation oxidative injury via antioxidant and intracellular calcium homeostasis.
Cui, J; Huang, XL; Li, CR; Ma, YJ; Wang, SQ; Wang, XW; Wu, L; Xun, SF; Zhao, HB; Zhong, ZY; Zhou, Z; Zhu, D, 2009
)
3.24
"Ginsenoside Rg1 (1) is a major active component of Panax notoginseng, a Chinese herb widely used in traditional Chinese medicine to improve learning and memory function. "( Ginsenoside Rg1 inhibits beta-secretase activity in vitro and protects against Abeta-induced cytotoxicity in PC12 cells.
Du, GH; Wang, YH, 2009
)
3.24
"Ginsenoside Rg1 (Rg1) acts as a neuroprotective agent against various insults, however, the underlying mechanism has not been fully elucidated yet. "( Ginsenoside Rg1 protection against β-amyloid peptide-induced neuronal apoptosis via estrogen receptor α and glucocorticoid receptor-dependent anti-protein nitration pathway.
Cui, R; Lin, J; Lou, Y; Pan, Z; Qian, J; Shen, Y; Wang, Q; Wang, Z; Wu, J; Yu, H; Yu, Y; Zhu, D; Zhu, W, 2012
)
3.26
"Ginsenoside Rg1 is an active principle isolated from Panax ginseng CA Meyer. "( [Study on the anti-apoptotic mechanism of ginsenoside Rg1 in cultured cortical neurons].
Li, JQ; Zhang, JT; Zhang, XG, 1997
)
2

Effects

Ginsenoside Rg1 has a neuroprotective effect on SCI and can improve motor dysfunction caused by injury. It has a potential protective role in lung diseases associated with glutamate toxicity.

Ginsenoside Rg1 has estrogen-like activities and has neuroprotective effects on the dopaminergic neurons in the 6-OHDA induced ovariectomyzed(OVX) rat model of Parkinson's disease (PD) The drug has inhibitory effects on myofibroblast differentiation and ECM production.

ExcerptReferenceRelevance
"Ginsenoside Rg1 has a neuroprotective effect on SCI and can improve motor dysfunction caused by injury. "( Ginsenoside Rg1 inhibits oxidative stress and inflammation in rats with spinal cord injury via Nrf2/HO-1 signaling pathway.
Mao, R; Xiong, M; Xu, J; Xu, Z; Yang, K; Zhang, Z; Zhong, D, 2022
)
3.61
"Ginsenoside Rg1 (Rg1) has a significant neuroprotective effect on animals with memory impairment."( Ginsenoside Rg1 improves Alzheimer's disease by regulating oxidative stress, apoptosis, and neuroinflammation through Wnt/GSK-3β/β-catenin signaling pathway.
Guo, Y; Jiao, J; Li, J; Wang, L; Wu, C; Yang, Y; Zhang, C; Zheng, H, 2022
)
2.89
"Ginsenoside Rg1 (Rg1) has a wide variety of therapeutic values for central nervous system (CNS) diseases for the neuron protective effects."( Ginsenoside Rg1 nanoparticle penetrating the blood-brain barrier to improve the cerebral function of diabetic rats complicated with cerebral infarction.
Cai, H; Liu, C; Shang, W; Shen, J; Zhang, B; Zhao, L; Zhao, Z, 2017
)
2.62
"Ginsenoside Rg1 has a protective role against CLP-induced polymicrobial sepsis by attenuating the proinflammatory response, enhancing innate immunity and preserving adaptive immunity. "( Ginsenoside Rg1 improves survival in a murine model of polymicrobial sepsis by suppressing the inflammatory response and apoptosis of lymphocytes.
Cao, L; Deng, X; Li, J; Tao, T; Tian, Y; Zhu, J; Zou, Y, 2013
)
3.28
"Ginsenoside Rg1 has a potential protective role in lung diseases associated with glutamate toxicity."( Protective effect of ginsenoside Rg1 on glutamate-induced lung injury.
Han, JZ; Li, C; Liu, HJ; Liu, Y; Luo, ZQ; Qin, XQ; Shen, L; Yue, SJ, 2007
)
2.1
"Ginsenoside Rg1 (Rg1) has the potential for diabetes and cardiovascular diseases therapy."( Ginsenoside Rg1 promoted the wound healing in diabetic foot ulcers via miR-489-3p/Sirt1 axis.
Cai, HA; Hu, FD; Huang, L; Huang, X; Liao, RY; Zhang, MS, 2021
)
2.79
"Ginsenoside Rg1 (Rg1) has been reported to exert potent anti‑aging effects due to its potential antioxidant and anti‑inflammatory activity."( Ginsenoside Rg1 ameliorates aging‑induced liver fibrosis by inhibiting the NOX4/NLRP3 inflammasome in SAMP8 mice.
Dong, X; Han, Y; Li, L; Li, W; Li, X; Li, Y; Yang, L; Zhang, D, 2021
)
2.79
"Ginsenoside Rg1 has a neuroprotective effect on SCI and can improve motor dysfunction caused by injury. "( Ginsenoside Rg1 inhibits oxidative stress and inflammation in rats with spinal cord injury via Nrf2/HO-1 signaling pathway.
Mao, R; Xiong, M; Xu, J; Xu, Z; Yang, K; Zhang, Z; Zhong, D, 2022
)
3.61
"Ginsenoside Rg1 (Rg1) has a significant neuroprotective effect on animals with memory impairment."( Ginsenoside Rg1 improves Alzheimer's disease by regulating oxidative stress, apoptosis, and neuroinflammation through Wnt/GSK-3β/β-catenin signaling pathway.
Guo, Y; Jiao, J; Li, J; Wang, L; Wu, C; Yang, Y; Zhang, C; Zheng, H, 2022
)
2.89
"Ginsenoside Rg1 has neuroprotective effects and influences cell proliferation and differentiation."( Effects of ginsenoside Rg1 on proliferation and directed differentiation of human umbilical cord mesenchymal stem cells into neural stem cells.
Li, Z; Luo, J; Wang, M; Xiao, L; Zou, K, 2022
)
1.83
"Ginsenoside Rg1 (Rg1) has traditionally been recognized as a protector of neuronal damages, preventing its degeneration."( Ginsenoside Rg1 promotes remyelination and functional recovery in demyelinating disease by enhancing oligodendrocyte precursor cells-mediated myelin repair.
Chen, Y; Du, X; Guo, Y; Li, M; Li, Q; Li, Y; Liu, L; Liu, Q; Ran, Q; Sun, L; Yang, L; Yang, Q; Zhu, X, 2022
)
2.89
"Ginsenoside Rg1 (Rg1) has been well-documented to be effective against ischemic/reperfusion (I/R) injury. "( Upregulation of HBXIP contributed to the anti-DND by ginsenoside Rg1 after global cerebral ischemia-reperfusion.
Chu, SF; He, HY; He, WB; Yuan, X; Zhang, Z; Zhang, ZY, 2023
)
2.6
"Ginsenoside Rg1 (Rg1) has been reported to improve DKD, but the mechanism is unclear."( Ginsenoside Rg1 treatment alleviates renal fibrosis by inhibiting the NOX4-MAPK pathway in T2DM mice.
Han, M; Ji, P; Li, W; Liu, Y; Shi, Q; Su, Y; Sun, R; Zhou, H, 2023
)
3.07
"Ginsenoside Rg1 has the potentials to prevent AD by alleviating depression, obesity, diabetes, and hypertension."( Ginsenoside Rg1, lights up the way for the potential prevention of Alzheimer's disease due to its therapeutic effects on the drug-controllable risk factors of Alzheimer's disease.
Ao, H; Chen, L; Liu, D; Peng, C; Tang, F; Wu, JJ; Xia, J; Yang, Y; Zhang, L, 2024
)
4.33
"Ginsenoside Rg1 has been proven to have effective anti-inflammatory and antiapoptotic properties."( Ginsenoside Rg1 attenuates cardiomyocyte apoptosis and inflammation via the TLR4/NF-kB/NLRP3 pathway.
Luo, M; Sun, H; Sun, Q; Tao, J; Xu, L; Yan, D; Zhao, H, 2020
)
2.72
"Ginsenoside Rg1 (GRg1) has neuroprotective effects on Alzheimer's disease (AD). "( Improving Alzheimer's disease by altering gut microbiota in tree shrews with ginsenoside Rg1.
Guo, Y; Jiao, J; Lu, J; Wang, L; Wu, C; Zeng, Y; Zhao, H; Zheng, H, 2020
)
2.23
"Ginsenoside Rg1 (G-Rg1) has been reported to be hepatoprotective in several liver injury models."( Hepatoprotection by Ginsenoside Rg1 in alcoholic liver disease.
He, X; Huang, W; Yang, C; Zhao, J, 2021
)
1.67
"Ginsenoside Rg1 (Rg1) has a wide variety of therapeutic values for central nervous system (CNS) diseases for the neuron protective effects."( Ginsenoside Rg1 nanoparticle penetrating the blood-brain barrier to improve the cerebral function of diabetic rats complicated with cerebral infarction.
Cai, H; Liu, C; Shang, W; Shen, J; Zhang, B; Zhao, L; Zhao, Z, 2017
)
2.62
"Ginsenoside Rg1 (Rg1) has been widely used in a broad range of cardiovascular and cerebral-vascular diseases because of its unique therapeutic properties. "( Ginsenoside Rg1 inhibits apoptosis by increasing autophagy via the AMPK/mTOR signaling in serum deprivation macrophages.
Chang, G; Guo, J; Ling, L; Lu, D; Sun, J; Sun, L; Sun, W; Yang, J; Yang, P; Zhang, L, 2018
)
3.37
"Ginsenoside Rg1 40?mg/kg has protective effects on cerebral injury induced by ischeamia/reperfusion, which might be related to the increased in the expression of BDNF in the hippocampal CA1 region, the down-regulation of the expression of IL-1??IL-6 and TNF-? in serum, the decreases in the contents of Glu and Asp in the brain tissue."( Protective effect and mechanism of ginsenoside Rg1 in cerebral ischaemia-reperfusion injury in mice.
Qu, LX; Wang, L; Zhai, ZZ; Zhao, H, 2018
)
2.2
"Ginsenoside Rg1 and mebicar have been reported to have broad efficacy spectrum, including anti-anxiety and anti-stress. "( Preventive Effect of Mebicar and Ginsenoside Rg1 on Neurobehavioral and Immunological Disruptions Caused by Intermittent Unpredictable Stress in Mice.
Cheon, K; Kim, CY; Kim, D; Kim, YG; Koo, H; Sin, SJ, 2018
)
2.2
"Ginsenoside Rg1 has been demonstrated to exhibit neuroprotective effects in various studies. "( Ginsenoside Rg1 Prevents Chronic Stress-Induced Depression-Like Behaviors and Neuronal Structural Plasticity in Rats.
Fan, C; Mao, X; Song, Q; Wang, P; Yang, L; Yu, H; Yu, S, 2018
)
3.37
"Ginsenoside Rg1 has a protective role against CLP-induced polymicrobial sepsis by attenuating the proinflammatory response, enhancing innate immunity and preserving adaptive immunity. "( Ginsenoside Rg1 improves survival in a murine model of polymicrobial sepsis by suppressing the inflammatory response and apoptosis of lymphocytes.
Cao, L; Deng, X; Li, J; Tao, T; Tian, Y; Zhu, J; Zou, Y, 2013
)
3.28
"Ginsenoside Rg1 (GRg1) has been considered to have therapeutic potential in promoting peripheral nerve regeneration and functional recovery after sciatic nerve injuries. "( The beneficial effect of ginsenoside Rg1 on Schwann cells subjected to hydrogen peroxide induced oxidative injury.
Chen, Y; Liu, J; Ma, J; Wang, Q; Xiang, L; Yu, H, 2013
)
2.14
"Ginsenoside Rg1 has the effect of delaying and treating Sca-1 (+) HSC/HPC aging during the serial transplantation. "( [Study on anti-aging effect of ginsenoside Rg1 in serial transplantation of hematopoietic stem cells and progenitor cells].
Cai, SZ; Jiang, R; Liu, DF; Liu, J; Wang, JW; Wang, YP; Yang, B; Yao, X; Zhou, Y, 2013
)
2.12
"Ginsenoside Rg1 has neuroprotective effect on ischemia-reperfusion injury in cultured hippocampal cells mediated by blocking calcium over-influx into neuronal cells and decreasing the nNOS activity after OGD exposure. "( Neuroprotective effects of ginsenoside Rg1 against oxygen-glucose deprivation in cultured hippocampal neurons.
He, B; He, Q; Sun, J; Wang, Q; Wang, W, 2014
)
2.14
"Ginsenoside Rg1 has been reported to possess anti-inflammatory activities, but the effects of Rg1 on the shear induced MCP-1 upregulation mechanism on endothelial cells (ECs) remain to be determined. "( Ginsenoside Rg1 downregulates the shear stress induced MCP-1 expression by inhibiting MAPK signaling pathway.
He, J; Li, YL, 2015
)
3.3
"Ginsenoside Rg1 has been demonstrated to have cardiovascular protective effects. "( Ginsenoside Rg1 ameliorates diabetic cardiomyopathy by inhibiting endoplasmic reticulum stress-induced apoptosis in a streptozotocin-induced diabetes rat model.
Gu, J; Liu, Q; Wu, S; Yang, Y; Yu, H; Zhen, J, 2016
)
3.32
"Ginsenoside Rg1 has been shown to exert a number of neuroprotective effects as demonstrated in various in vivo and in vitro studies."( The effects of ginsenoside Rg1 on chronic stress induced depression-like behaviors, BDNF expression and the phosphorylation of PKA and CREB in rats.
Cheng, Z; Fan, C; Liu, Z; Qi, Y; Yu, SY; Zhu, X, 2016
)
1.51
"Ginsenoside Rg1 (G-Rg1) has been demonstrated to exert antioxidative and prosurvival effects in many cell types."( Ginsenoside Rg1 protects human umbilical cord blood-derived stromal cells against tert-Butyl hydroperoxide-induced apoptosis through Akt-FoxO3a-Bim signaling pathway.
Chen, L; Chen, X; Liu, Y; Wang, L; Wang, Y; Yi, L, 2016
)
2.6
"Ginsenoside Rg1 has been reported to improve cognitive function in many memory-impaired animal models. "( Improvement of memory in mice and increase of hippocampal excitability in rats by ginsenoside Rg1's metabolites ginsenoside Rh1 and protopanaxatriol.
Chen, J; Chen, NH; Chu, SF; Wang, XY; Wang, YS; Wang, YZ; Zhang, JT, 2009
)
2.02
"Ginsenoside Rg1 has no specific absorption locus in intestine of rat and ginsenoside Rb1 has specific absorption locus of jejunum."( [Studies on influence factors of gnsenoside Rg1 and Rb1 absorption in intestines of rats].
Ji, Y; Li, W; Nan, L; Sun, X; Sun, Z, 2009
)
1.07
"Ginsenoside Rg1 has estrogen-like activities and has neuroprotective effects on the dopaminergic neurons in the 6-OHDA induced ovariectomyzed(OVX) rat model of Parkinson's disease (PD). "( [The protective effect of ginsenoside Rg1 on dopaminergic neurons of substantia in the ovariectomized rat model of Parkinson's disease].
Chen, WF; Huang, WX; Liu, LX; Xie, JX; Xu, L, 2008
)
2.09
"The ginsenoside Rg1 has inhibitory effects on myofibroblast differentiation and ECM production."( Inhibitory effect of ginsenoside Rg1 on extracellular matrix production via extracellular signal-regulated protein kinase/activator protein 1 pathway in nasal polyp-derived fibroblasts.
Cho, JS; Lee, HM; Moon, JH; Moon, YM; Park, IH; Um, JY, 2012
)
1.18
"Ginsenoside Rg1 has a potential protective role in lung diseases associated with glutamate toxicity."( Protective effect of ginsenoside Rg1 on glutamate-induced lung injury.
Han, JZ; Li, C; Liu, HJ; Liu, Y; Luo, ZQ; Qin, XQ; Shen, L; Yue, SJ, 2007
)
2.1

Actions

Ginsenoside Rg1 from ginseng plays a crucial role in neuroprotective effects through anti-inflammation and attenuating the aggregation of abnormal α-synuclein. GinsenosideRg1 promotes the proliferation and viability of hUCMSCs in the process of differentiation into NSCs but also improves the differentiation efficiency.

ExcerptReferenceRelevance
"Ginsenoside Rg1 from ginseng plays a crucial role in neuroprotective effects through anti-inflammation and attenuating the aggregation of abnormal α-synuclein."( Ginsenoside Rg1 Plays a Neuroprotective Role in Regulating the Iron-Regulated Proteins and Against Lipid Peroxidation in Oligodendrocytes.
Chen, NH; Chen, Y; Li, YY; Wang, S; Yuan, YH; Zhou, T, 2022
)
2.89
"Ginsenoside Rg1 not only promotes the proliferation and viability of hUCMSCs in the process of differentiation into NSCs but also improves the differentiation efficiency. "( Effects of ginsenoside Rg1 on proliferation and directed differentiation of human umbilical cord mesenchymal stem cells into neural stem cells.
Li, Z; Luo, J; Wang, M; Xiao, L; Zou, K, 2022
)
2.55
"Ginsenoside Rg1 can evidently inhibit UUO-induced renal interstitial fibrosis in rat, which may be related to the down regulation of TGF-beta1 expression."( [The effect of ginsenoside Rg1 on the renal interstitial fibrosis of UUO rat].
Deng, Y; Fan, JM; Liu, HC; Xie, XS; Zuo, C, 2008
)
2.14
"Ginsenoside Rg1 could inhibit the expression of P-Tau to slow the formation of neurofibrillary tangles and could inhibit the expression of caspase-3 to inhibit neuronal apoptosis to protect the nerve cells, so as to play the role of anti-dementia."( [Experimental research on effect of gensenoside Rg1 on expressions of P-Tau and caspase-3 in brain slices from AD model rats].
Li, X; Quan, Q; Yuan, H; Zhang, X, 2010
)
1.8
"Ginsenoside Rg1 promotes antioxidative protection and intracellular calcium homeostasis in cardiomyocytes hypoxia/reoxygenation (H/R) model. "( Ginsenoside Rg1 inhibits autophagy in H9c2 cardiomyocytes exposed to hypoxia/reoxygenation.
Fan, Y; Liu, ML; Zhang, ZL, 2012
)
3.26
"Ginsenoside Rg1 could enhance NO production and the expression of eNOS mRNA in TNF-alpha stimulated HUVECs. "( Ginsenoside Rg1-induced alterations in gene expression in TNF-alpha stimulated endothelial cells.
Huang, J; Lü, JP; Ma, ZC; Wang, SQ; Wang, SR; Yang, J, 2004
)
3.21

Treatment

Ginsenoside Rg1 (10 µM) treated breast cancer cells were exposed to 8 nM of doxorubicin, and the chemosensitizing potential was measured by cell-based assays. The treatment significantly decreased TAC-induced myocardial fibrosis and left ventricular hypertrophy, and preserved cardiac function.

ExcerptReferenceRelevance
"Ginsenoside Rg1 (10 µM) treated breast cancer cells were exposed to 8 nM of doxorubicin, and the chemosensitizing potential was measured by cell-based assays."( Ginsenoside RG1 augments doxorubicin-induced apoptotic cell death in MDA-MB-231 breast cancer cell lines.
Gao, F; Huang, J; Liu, S; Yin, Z; Zhang, R, 2022
)
2.89
"Ginsenoside Rg1 treatment could reverse hypoxia-induced EndMT and inflammation by regulating CCN1 and has potential value in the prevention and treatment of HPH."( Ginsenoside Rg1 ameliorates hypoxia-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition and inflammation by regulating CCN1.
Liu, Y; Lu, ML; Tang, BL; Wang, HX; Zhang, JL, 2023
)
3.07
"Ginsenoside Rg1 treatment before I/S intervention significantly ameliorated learning and memory performance, reduced ROS levels and improved the OCR, MMP, expression and deacetylation activity of Sirt3."( Ginsenoside Rg1 attenuates isoflurane/surgery-induced cognitive disorders and sirtuin 3 dysfunction.
Miao, HH; Tian, M; Wang, HX; Wang, M; Xue, FS, 2019
)
2.68
"Ginsenoside Rg1 treatment suppressed H/R-induced apoptosis and caspase-3 activation. "( Ginsenoside Rg1 Protects Cardiomyocytes Against Hypoxia/Reoxygenation Injury via Activation of Nrf2/HO-1 Signaling and Inhibition of JNK.
Chen, Y; Li, Q; Tang, Y; Xiang, Y; Zhang, Y, 2017
)
3.34
"Ginsenoside Rg1 treatment remarkably suppressed apoptosis rate of LPS-induced A549 cells, relieved mouse lung tissue damage, and elevated survival rate. "( Ginsenoside Rg1 Regulates SIRT1 to Ameliorate Sepsis-Induced Lung Inflammation and Injury via Inhibiting Endoplasmic Reticulum Stress and Inflammation.
Gao, M; Peng, Y; Wang, QL; Xiao, XZ; Xing, W; Yang, L; Yang, MS, 2019
)
3.4
"Ginsenoside Rg1 treatment significantly decreased TAC-induced myocardial fibrosis and left ventricular hypertrophy, and preserved cardiac function. "( The ginsenoside Rg1 prevents transverse aortic constriction-induced left ventricular hypertrophy and cardiac dysfunction by inhibiting fibrosis and enhancing angiogenesis.
Bourantas, CV; Chen, SL; Iqbal, J; Li, JJ; Li, MH; Muramatsu, T; Su, XY; Tian, NL; Zhang, XL; Zhang, YJ, 2013
)
2.39
"Ginsenoside Rg1 treatment of diabetic rats was associated with reduced oxidative stress and attenuated myocardial apoptosis, suggesting that ginsenoside Rg1 may be of potential preventative and therapeutic value for cardiovascular injury in diabetic patients."( Ginsenoside Rg1 ameliorates oxidative stress and myocardial apoptosis in streptozotocin-induced diabetic rats.
Gu, JN; Pang, B; Wu, SS; Yu, HT; Zhen, J, 2015
)
2.58
"Ginsenoside Rg1 treatment also reverted the decrease of alpha7 nicotinic acetylcholine receptor (α7 nAChR) protein expression in the prefrontal cortex (PFC) and hippocampus of LPS-treated rats."( Ameliorative Effect of Ginsenoside Rg1 on Lipopolysaccharide-Induced Cognitive Impairment: Role of Cholinergic System.
Jin, Y; Peng, J; Wang, T; Wang, X; Zhang, D, 2017
)
1.49
"Ginsenoside Rg1 and E2-treatment significantly ameliorated these deteriorations in AD rats."( Effects of ginsenoside Rg1 or 17β-estradiol on a cognitively impaired, ovariectomized rat model of Alzheimer's disease.
Dong, L; Gong, L; Li, H; Li, S; Li, Y; Wang, J; Wang, Y; Wu, Z; Xing, Y; Zhang, X, 2012
)
1.49
"Ginsenoside Rg1 treatment significantly increased the CUMS-induced decrease in sucrose consumption, horizontal and vertical activities."( [Effect of ginsenoside Rg1 on behaviors and hippocampal amino acids in depressive-like rats].
Guo, JY; Wu, HF; Zhu, CH, 2012
)
1.49
"Ginsenoside Rg1 pretreatment had significant effects of attenuating these changes."( Ginsenoside Rg1 delays tert-butyl hydroperoxide-induced premature senescence in human WI-38 diploid fibroblast cells.
Chen, X; Fang, Y; Zhang, J; Zhao, C; Zhu, Y, 2008
)
2.51
"Treatment with ginsenoside Rg1, recombinant CCN1, BAY-11-7082, and SB-431542 could prevent hypoxia-induced vascular remodeling, reduce the expression of the hypoxia-induced inflammatory cytokines TNF-α and IL-1β, inhibit the expression of the mesenchymal markers α-SMA and Vimentin and restore the expression of the endothelial markers CD31 and VE-cadherin to improve hypoxia-induced EndMT, which may be associated with the upregulation of CCN1 protein expression and downregulation of p-NFκB p65, TGF-β1, and p-Smad 2/3 in rats and cells."( Ginsenoside Rg1 ameliorates hypoxia-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition and inflammation by regulating CCN1.
Liu, Y; Lu, ML; Tang, BL; Wang, HX; Zhang, JL, 2023
)
2.69
"Treatment with ginsenoside Rg1 reduces the expression of TIF1 and increases the expression of glucose-regulated protein 78."( Ginsenoside Rg1 Prevents Doxorubicin-Induced Cardiotoxicity through the Inhibition of Autophagy and Endoplasmic Reticulum Stress in Mice.
Li, CB; Li, P; Liu, QL; Xu, ZM; Yang, H, 2018
)
2.26
"Treatment with ginsenoside Rg1 (10-20 mg/kg) significantly reduced serum cTnI levels compared with DM control group (all P < 0.01)."( Ginsenoside Rg1 ameliorates diabetic cardiomyopathy by inhibiting endoplasmic reticulum stress-induced apoptosis in a streptozotocin-induced diabetes rat model.
Gu, J; Liu, Q; Wu, S; Yang, Y; Yu, H; Zhen, J, 2016
)
2.22
"Pre-treatment with ginsenoside Rg1 resulted in an enhancement of survival, and significant rescue occurred at the concentration of 0.01 microM on cell viability against 6-OHDA-induced neurotoxicity."( Ginsenoside Rg1 protects against 6-OHDA-induced neurotoxicity in neuroblastoma SK-N-SH cells via IGF-I receptor and estrogen receptor pathways.
Chen, WF; Gao, QG; Wong, MS; Xie, JX, 2009
)
2.11
"Pretreatment with ginsenoside Rg1 (60-120 microM) reduced lactate dehydrogenase release and increased cell viability in a dose-dependent manner."( Ginsenoside Rg1 protects rat cardiomyocyte from hypoxia/reoxygenation oxidative injury via antioxidant and intracellular calcium homeostasis.
Cui, J; Huang, XL; Li, CR; Ma, YJ; Wang, SQ; Wang, XW; Wu, L; Xun, SF; Zhao, HB; Zhong, ZY; Zhou, Z; Zhu, D, 2009
)
2.12
"Pretreatment with ginsenoside Rg1 had obvious neuroprotective effects on cell viability against 6-OHDA-induced toxicity. "( Ginsenoside Rg1 protects against 6-OHDA-induced toxicity in MES23.5 cells via Akt and ERK signaling pathways.
Chen, WF; Ge, KL; Wong, MS; Xie, JX, 2010
)
2.14
"The treatment of ginsenoside Rg1 significantly enhanced glucose uptake in the differentiated muscle cells and the relative abundance of GLUT4 through the adenosine-monophosphate-activated protein kinase pathway."( Ginsenoside Rg1 promotes glucose uptake through activated AMPK pathway in insulin-resistant muscle cells.
Kim, KJ; Lee, BY; Lee, HM; Lee, OH, 2012
)
2.15
"The treatment of ginsenoside Rg1 at a dose of 2.5 µmol/L decreased the levels of Aβ1-40 and Aβ1-42 (13.3 ± 4.3) ng/ml vs (12.0 ± 5.4) ng/ml in N2a/APP695 cells, decreased the protein level of BACE1 (BACE1/β-actin 0.26 ± 0.05), increased the protein level of NF-κB p65 (p-p65/p65 0.93 ± 0.02) and resulted in the translocation of NF-κB from cytoplasm to nucleus. "( [Mechanism of ginsenoside Rg1 regulating the activity of β secretase in N2a/APP695 cells].
Chen, LM; Chen, XC; Lin, N; Zhang, J; Zhu, YG, 2012
)
1.08
"Pretreatment with ginsenoside Rg1 was shown to prevent the loss of Nissl staining neurons and TH-positive neurons, and decrease the percent of TUNEL-positive. "( [Possible mechanisms of the protective effect of ginsenoside Rg1 on apoptosis in substantia nigra neurons].
Chen, XC; Chen, Y, 2002
)
0.9
"Pretreatment with ginsenoside Rg1 markedly reduced the generation of dopamine-induced reactive oxygen species and the release of mitochondrial cytochrome c into the cytosol, and subsequently inhibited the activation of caspase-3."( Ginsenoside Rg1 attenuates dopamine-induced apoptosis in PC12 cells by suppressing oxidative stress.
Chen, LM; Chen, XC; Chen, Y; Fang, F; Huang, C; Zhao, CH; Zhou, YC; Zhu, LA; Zhu, YG, 2003
)
2.09
"Treatment with ginsenoside Rg1, which blocked the cell cycle in the G1-phase, induced a downregulation of cyclin D1 and an upregulation in the expression of p53, p21(WAF/CIP1), and p27(KIP1)."( Ginsenoside Rg1 inhibits tumor necrosis factor-alpha (TNF-alpha)-induced human arterial smooth muscle cells (HASMCs) proliferation.
Wang, SQ; Zhang, HS, 2006
)
2.12

Toxicity

ExcerptReferenceRelevance
"Formaldehyde (FA), a common environmental pollutant, has toxic effects on central nervous system."( Induction of endoplasmic reticulum stress and the modulation of thioredoxin-1 in formaldehyde-induced neurotoxicity.
Bai, J; Luo, FC; Lv, T; Nakamura, H; Qi, L; Wang, SD; Yodoi, J; Zhou, J, 2012
)
0.38
" The LD50 in mice was 1747 mg/kg, which was more than one hundred times higher than the effective dose."( The Safety Evaluation of Salvianolic Acid B and Ginsenoside Rg1 Combination on Mice.
Cho, K; Deng, Y; Guo, DA; Jiang, B; Li, X; Liu, X; Ma, H; Teng, F; Wang, L; Wu, P; Wu, W; Xu, F; Yang, M; Yu, H; Zhao, Q, 2015
)
0.67

Pharmacokinetics

LC-MS/MS method was established to analyze five ingredients. Results suggested pharmacokinetic and pharmacodynamic drug-drug interactions between ginsenoside Rg1, Rb1 and schisandrin.

ExcerptReferenceRelevance
" The pharmacokinetic profiles of the main PNS are still not accurately investigated."( Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats.
Chen, DF; Fang, XL; Xu, QF, 2003
)
0.32
"Ginsenosides Rg1 and Re in plasma were determined by LC/MS/MS and the pharmacokinetic parameters were calculated."( [Pharmacokinetics of ginsenosides Rg1 and Re in Shenmai injection].
Deng, YH; Feng, Y; Liang, WX; Liu, YM; Yang, L; Zeng, X, 2005
)
0.33
" The distribution and elimination of Rg1 and Re were rapid after iv infusion of Shenmai injection in volunteers, the pharmacokinetic characteristics were fitted with the two-compartment model."( [Pharmacokinetics of ginsenosides Rg1 and Re in Shenmai injection].
Deng, YH; Feng, Y; Liang, WX; Liu, YM; Yang, L; Zeng, X, 2005
)
0.33
"To investigate the pharmacokinetic course of intranasal powders of Panax notoginseng Saponins (PNS) in a rat model and its protective effects against cardio-cerebrovascular diseases administrated in the form of its suspension."( [The pharmacokinetics and pharmacodynamics of intranasal preparation of Panax notoginseng Saponins].
Fang, XL; Sha, XY; Wu, YJ; Zhu, XY, 2005
)
0.33
"Enzyme-linked immunosorbent assay (ELISA) systems using anti-ginsenoside Rb1 (G-Rb1) and Rg1 (G-Rg1) monoclonal antibodies (MAbs) were established for pharmacokinetic investigations of G-Rb1 and G-Rg1 in rat serum."( Pharmacokinetic study of ginsenosides Rb1 and Rg1 in rat by ELISA using anti-ginsenosides Rb1 and Rg1 monoclonal antibodies.
Chao, Z; Shoyama, Y; Tanaka, H, 2006
)
0.33
"To study the pharmacokinetics of ginsenosides Rg1 and its metabolites after iv and oral administration in Wistar rats, the LC-MS/MS method was selected to determine ginsenosides Rg1 and its metabolites in plasma and their pharmacokinetic parameters were calculated."( [Pharmacokinetics of ginsenosides Rg1 and its metabolites in rats].
Feng, L; Hu, CJ; Yu, LY, 2010
)
0.36
" The concentrations of Rb1, Rg1 and R1 were measured by high performance liquid chromatography (HPLC), and statistic program DAS was applied to the calculation of pharmacokinetic parameters."( [In vivo distribution and pharmacokinetics of multiple effective components contained in Panax notoginseng saponins after intratympanic administration].
Chen, G; Hou, S; Mu, L; Nan, H; Zhang, X, 2011
)
0.37
" However, the pharmacokinetic parameters showed significant differences between the three components."( [In vivo distribution and pharmacokinetics of multiple effective components contained in Panax notoginseng saponins after intratympanic administration].
Chen, G; Hou, S; Mu, L; Nan, H; Zhang, X, 2011
)
0.37
" The developed method was suitable for the quantification of EsA and successfully applied to the pharmacokinetic study of EsA after an oral administration to beagle dogs."( Determination of esculentoside A in dog plasma by LC-MS/MS method: application to pre-clinical pharmacokinetics.
Chang, H; Chen, X; Fan, G; Guan, X; Sun, F; Zhang, W, 2013
)
0.39
" Compared with intragastric administration, intranasal administration resulted in a shorter tmax (0."( Pharmacokinetics and efficiency of brain targeting of ginsenosides Rg1 and Rb1 given as Nao-Qing microemulsion.
Chen, G; Cheng, JY; Dian, SN; Huang, SL; Li, T; Liang, RC; Lv, XX; Shu, YJ; Yang, F; Yang, MQ, 2015
)
0.42
" 3P97 software was used to calculate pharmacokinetic parameters."( [Pharmacokinetics and bioavailability of ginsenoside Rg1 in rats].
Huang, XZ; Liang, JQ; Tan, ZY; Xiong, WN, 2013
)
0.66
" It is valuable to investigate their pharmacokinetic and pharmacodynamic behavior and potential synergistic effect for better drug development and clinical application."( A pharmacokinetic and pharmacodynamic study of drug-drug interaction between ginsenoside Rg1, ginsenoside Rb1 and schizandrin after intravenous administration to rats.
Cheng, Y; Fan, X; Guo, W; Li, Z; Shao, Q; Zhan, S, 2014
)
0.63
"Pharmacokinetic and nitric oxide (NO) release pharmacodynamic drug-drug interactions of ginsenoside Rg1, ginsenoside Rb1 and schisandrin were studied after intravenous administration of each compound with the dose of 10 mg/kg and their mixture with the total dose of 10 mg/kg to isoproterenol (ISO)-induced myocardial ischemia rats."( A pharmacokinetic and pharmacodynamic study of drug-drug interaction between ginsenoside Rg1, ginsenoside Rb1 and schizandrin after intravenous administration to rats.
Cheng, Y; Fan, X; Guo, W; Li, Z; Shao, Q; Zhan, S, 2014
)
0.85
"The result obtained from this study suggested pharmacokinetic and pharmacodynamic drug-drug interactions between ginsenoside Rg1, Rb1 and schisandrin."( A pharmacokinetic and pharmacodynamic study of drug-drug interaction between ginsenoside Rg1, ginsenoside Rb1 and schizandrin after intravenous administration to rats.
Cheng, Y; Fan, X; Guo, W; Li, Z; Shao, Q; Zhan, S, 2014
)
0.84
" Pharmacokinetic parameters were estimated using non-compartmental methods."( In vivo distribution and pharmacokinetics of multiple active components from Danshen and Sanqi and their combination via inner ear administration.
Chen, G; Long, W; Mu, L; Wen, L; Yang, F; Zhang, SC, 2014
)
0.4
" The values of Cmax and AUC(0-t) after IT were significantly higher than IV."( In vivo distribution and pharmacokinetics of multiple active components from Danshen and Sanqi and their combination via inner ear administration.
Chen, G; Long, W; Mu, L; Wen, L; Yang, F; Zhang, SC, 2014
)
0.4
" Co-administration of Danshen and Sanqi could cause significant pharmacokinetic herb-herb interactions in guinea pigs."( In vivo distribution and pharmacokinetics of multiple active components from Danshen and Sanqi and their combination via inner ear administration.
Chen, G; Long, W; Mu, L; Wen, L; Yang, F; Zhang, SC, 2014
)
0.4
" The pharmacokinetic parameters were then determined using non-compartmental models."( Pharmacokinetics of ginsenoside Rg1 in rat medial prefrontal cortex, hippocampus, and lateral ventricle after subcutaneous administration.
Gao, Y; Li, KX; Li, M; Liu, Y; Qi, WY; Shi, AX; Xue, W, 2016
)
0.76
" The pharmacokinetic studies of FXT and PN were performed using the established method with the pharmacokinetic parameters being determined by non-compartmental analysis."( Effect of compatible herbs on the pharmacokinetics of effective components of Panax notoginseng in Fufang Xueshuantong Capsule.
Huang, JM; Li, MY; Ma, CH; Pang, HH; Tang, MK; Wang, Y,
)
0.13
" The analytical method was successfully applied to a pharmacokinetic study of the multi-components after oral administration of Sanjie Zhentong Capsule in rats."( Simultaneous determination of ten bioactive constituents of Sanjie Zhentong Capsule in rat plasma by ultra-high-performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study.
Hu, JH; Huang, W; Li, D; Li, J; Pan, Y; Wang, Y; Wang, ZZ; Xiao, W, 2017
)
0.46
"LC-MS/MS method was established to analyze five ingredients, notoginsenoside R1 (R1), ginsenoside Rg1 (Rg1), ginsenoside Rb1 (Rb1), ginsenoside Re (Re), and ginsenoside Rd (Rd), in rats' plasma to describe the pharmacokinetic parameters of PNS."( Pharmacokinetics of Panax notoginseng Saponins in Adhesive and Normal Preparation of Fufang Danshen.
Bai, J; Chen, XN; Du, SY; Li, DQ; Li, PY; Lu, Y; Tian, ZH; Wu, YL; Yu, GY; Zeng, YY; Zhao, MD, 2018
)
0.7
"The pharmacokinetic parameters were significantly different after oral administration three formulations."( Pharmacokinetics of Panax notoginseng Saponins in Adhesive and Normal Preparation of Fufang Danshen.
Bai, J; Chen, XN; Du, SY; Li, DQ; Li, PY; Lu, Y; Tian, ZH; Wu, YL; Yu, GY; Zeng, YY; Zhao, MD, 2018
)
0.48
" The aim of this study was to investigate the pharmacokinetic effects of ginsenoside Rg1 on the three types of alkaloids and to provide evidences for their compatibility mechanism."( Pharmacokinetic effects of ginsenoside Rg1 on aconitine, benzoylaconine and aconine by UHPLC-MS/MS.
An, R; Liang, K; Wang, X; Xu, Y; Yang, L; Zhang, H, 2020
)
1.09
" In view of its undefined applicable population and dosage, a population pharmacokinetic (PPK) study is required."( UFLC-MS/MS Determination and Population Pharmacokinetic Study of Tanshinol, Ginsenoside Rb1 and Rg1 in Rat Plasma After Oral Administration of Compound Danshen Dripping Pills.
Chu, Y; Jin, T; Li, S; Liu, Z; Ma, X; Sun, H; Wang, G; Wang, X; Yang, J; Zhou, S, 2020
)
0.56
"As a preliminary exploration toward the clinical population pharmacokinetic research, this study provides a reference for the population pharmacokinetic study of traditional CMM."( UFLC-MS/MS Determination and Population Pharmacokinetic Study of Tanshinol, Ginsenoside Rb1 and Rg1 in Rat Plasma After Oral Administration of Compound Danshen Dripping Pills.
Chu, Y; Jin, T; Li, S; Liu, Z; Ma, X; Sun, H; Wang, G; Wang, X; Yang, J; Zhou, S, 2020
)
0.56
" In comparison with Danshen and Sanqi alone, there were significant differences in pharmacokinetic parameters of TS IIA, SAB and Rg1, and the brain distribution of SAB and TS IIA when Danshen, Sanqi and borneol were administrated together."( The effects of borneol on the pharmacokinetics and brain distribution of tanshinone IIA, salvianolic acid B and ginsenoside Rg
Jia, LJ; Li, JP; Liu, SL; Shi, LY; Wang, H; Xie, BP; Zhang, J, 2021
)
0.62
" However, the pharmacokinetic characteristics of its major bioactive components under pathological conditions are unclear."( Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS.
Chen, L; Chen, Y; Jiang, Y; Kong, M; Li, J; Wang, Q; Wei, N; Xu, L; Yuan, C, 2023
)
0.91
"This method was successfully applied to the pharmacokinetic investigation of seven major components of C-QSP and P-QSP following oral administration in CHF model rats."( Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS.
Chen, L; Chen, Y; Jiang, Y; Kong, M; Li, J; Wang, Q; Wei, N; Xu, L; Yuan, C, 2023
)
0.91
"The pharmacokinetic parameters of bioactive components were significantly changed for better bioavailability and absorption, longer lasting time elimination, which were beneficial for enhancing therapeutic efficacy in the P-QSP group."( Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS.
Chen, L; Chen, Y; Jiang, Y; Kong, M; Li, J; Wang, Q; Wei, N; Xu, L; Yuan, C, 2023
)
0.91

Compound-Compound Interactions

Ginsenoside Rg1, Rb1 and schisandrin were studied after intravenous administration of each compound with the dose of 10 mg/kg to isoproterenol ( ISO)-induced myocardial ischemia rats. The study suggested pharmacokinetic and pharmacodynamic drug-drug interactions.

ExcerptReferenceRelevance
"Pharmacokinetic and nitric oxide (NO) release pharmacodynamic drug-drug interactions of ginsenoside Rg1, ginsenoside Rb1 and schisandrin were studied after intravenous administration of each compound with the dose of 10 mg/kg and their mixture with the total dose of 10 mg/kg to isoproterenol (ISO)-induced myocardial ischemia rats."( A pharmacokinetic and pharmacodynamic study of drug-drug interaction between ginsenoside Rg1, ginsenoside Rb1 and schizandrin after intravenous administration to rats.
Cheng, Y; Fan, X; Guo, W; Li, Z; Shao, Q; Zhan, S, 2014
)
0.85
"The result obtained from this study suggested pharmacokinetic and pharmacodynamic drug-drug interactions between ginsenoside Rg1, Rb1 and schisandrin."( A pharmacokinetic and pharmacodynamic study of drug-drug interaction between ginsenoside Rg1, ginsenoside Rb1 and schizandrin after intravenous administration to rats.
Cheng, Y; Fan, X; Guo, W; Li, Z; Shao, Q; Zhan, S, 2014
)
0.84
" Our results showed that, based on the 50% inhibiting concentration (IC50), AST IV combined with Rg1 at a 1:1 ratio resulted in a synergistic effect, whereas the combination of the two had an antagonistic effect on autophagy at ratios of 1:2 and 2:1."( Synergism and mechanism of Astragaloside IV combined with Ginsenoside Rg1 against autophagic injury of PC12 cells induced by oxygen glucose deprivation/reoxygenation.
Deng, CQ; Ding, H; Huang, XP; Li, JX; Liu, XD; Tang, B; Tang, YH; Yang, XQ, 2017
)
0.7
"To observe the effect of ginsenoside Rg1 on the acute lung injury of sepsis in combination with the antibiotic imipenem in a mouse model of sepsis that induced by cecal puncture."( [Experimental Study of Ginsenoside Rg1 Combined with Antibiotics in the Treatment of Acute Lung Injury in Mice with Sepsis].
Xu, QP; Zhang, ZB, 2020
)
1.17
" It has a better therapeutic effect when combined with antibiotics."( [Experimental Study of Ginsenoside Rg1 Combined with Antibiotics in the Treatment of Acute Lung Injury in Mice with Sepsis].
Xu, QP; Zhang, ZB, 2020
)
0.87
" To investigate the effects of Rg1 in combination with mannitol protects neurons against glutamate-induced ER stress via the PERK-eIF2 -ATF4 signaling pathway."( Rg1 in combination with mannitol protects neurons against glutamate-induced ER stress via the PERK-eIF2 α-ATF4 signaling pathway.
Gu, Y; Jiang, C; Ren, K; Wang, L; Yao, Q, 2020
)
0.56
" A microdialysis combined with UPLC-MS/MS method was first established to compare the pharmacokinetics of seven major bioactive components in CHF model rats after oral administration of C-QSP and P-QSP."( Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS.
Chen, L; Chen, Y; Jiang, Y; Kong, M; Li, J; Wang, Q; Wei, N; Xu, L; Yuan, C, 2023
)
0.91

Bioavailability

The oral relative bioavailability of ginsenoside Rg1 and Rb1 of PNS was enhanced remarkably by the lipid-based formulations.

ExcerptReferenceRelevance
"After administration, Rgl concentration in the serum was analyzed by HPLC and the absolute bioavailability was calculated."( [The pharmacokinetics and pharmacodynamics of intranasal preparation of Panax notoginseng Saponins].
Fang, XL; Sha, XY; Wu, YJ; Zhu, XY, 2005
)
0.33
"The in vivo course of Rgl in rats conformed to two-compartment model after intranasal administration of PNS suspension and the absolute bioavailability was 103."( [The pharmacokinetics and pharmacodynamics of intranasal preparation of Panax notoginseng Saponins].
Fang, XL; Sha, XY; Wu, YJ; Zhu, XY, 2005
)
0.33
"Elimination in the stomach, large intestine and liver contributed to the low oral bioavailability of Rg1, but low membrane permeability might be a more important factor in determining the extent of absorption."( Difference in oral absorption of ginsenoside Rg1 between in vitro and in vivo models.
Fang, XL; Han, M, 2006
)
0.62
" The elimination in stomach, large intestine and liver contributed to the low bioavailability of PNS, but the low membrane permeability might be a more important factor dominating the extent of absorption."( [Mechanism of oral absorption of panaxnotoginseng saponins].
Bai, ZH; Fang, XL; Han, LM; Han, M; Wang, QS, 2006
)
0.33
" Therefore, poor intestinal absorption is a primary reason for the low bioavailability of both Rg1 and Rb1."( [Comparison between the characteristics of absorption and pharmacokinetic behavior of ginsenoside Rg1 and ginsenoside Rb, of Panax notoginseng saponins].
Fang, XL; Fu, S; Han, M, 2007
)
0.56
"PNS-Phospholipid complex and a lipid-based formulation by dissolving the complex in the medium chain fattyglycerides were prepared, and their oral relative bioavailability was determined in rats and compared with an aqueous solution of PNS for each component."( The use of lipid-based formulations to increase the oral bioavailability of Panax notoginseng saponins following a single oral gavage to rats.
Guo, J; Huang, L; Meng, B; Ping, Q; Xiong, J, 2008
)
0.35
" The experimental result in rats in vivo showed that the oral relative bioavailability was enhanced remarkably by these lipid-based formulations composed of the PNS-Phospholipid complex and various esters."( The use of lipid-based formulations to increase the oral bioavailability of Panax notoginseng saponins following a single oral gavage to rats.
Guo, J; Huang, L; Meng, B; Ping, Q; Xiong, J, 2008
)
0.35
"The oral relative bioavailability of ginsenoside Rg1 and Rb1 of PNS was enhanced remarkably by the lipid-based formulations."( The use of lipid-based formulations to increase the oral bioavailability of Panax notoginseng saponins following a single oral gavage to rats.
Guo, J; Huang, L; Meng, B; Ping, Q; Xiong, J, 2008
)
0.62
" Transport of Rg1 across Caco-2 cells was also studied and an oral bioavailability study of Rg1 was carried out in rats."( Enhancement by adrenaline of ginsenoside Rg1 transport in Caco-2 cells and oral absorption in rats.
Guo, J; Huang, L; Meng, B; Ping, Q; Sun, M; Wang, S; Xiong, J, 2009
)
0.64
" The co-administration with adrenaline in rats showed that the oral bioavailability was increased remarkably relative to the aqueous solution."( Enhancement by adrenaline of ginsenoside Rg1 transport in Caco-2 cells and oral absorption in rats.
Guo, J; Huang, L; Meng, B; Ping, Q; Sun, M; Wang, S; Xiong, J, 2009
)
0.64
" After being administrated intraduodenally to rats, most of MEs can enhance the intestinal absorption of Rg(1) to various extents with relative bioavailability (F(re)) ranging from 268 to 1270% using drug solution as control."( Evaluation of intestinal absorption of ginsenoside Rg1 incorporated in microemulison using parallel artificial membrane permeability assay.
Fang, XL; Fu, S; Gao, JQ; Han, M, 2009
)
0.62
" Meanwhile, ginsenoside Rb1 is the P-gp substrate, and could increase its fraction of bioavailability by corporation with P-gp inhibitor."( [Studies on influence factors of gnsenoside Rg1 and Rb1 absorption in intestines of rats].
Ji, Y; Li, W; Nan, L; Sun, X; Sun, Z, 2009
)
0.35
"To investigate the pharmacokinetics and bioavailability of ginsenoside Rg1 in rats."( [Pharmacokinetics and bioavailability of ginsenoside Rg1 in rats].
Huang, XZ; Liang, JQ; Tan, ZY; Xiong, WN, 2013
)
0.9
"The oral bioavailability of ginsenoside Rg1 is very low."( [Pharmacokinetics and bioavailability of ginsenoside Rg1 in rats].
Huang, XZ; Liang, JQ; Tan, ZY; Xiong, WN, 2013
)
0.95
" Saponins are very soluble in water but poorly absorbed when orally administrated."( Preparation and characterization of mucoadhesive enteric-coating ginsenoside-loaded microparticles.
Baek, JS; Cho, CW; Hwang, SJ; Kim, DC; Lee, CA; Park, JS; Yeon, WG, 2015
)
0.42
" The application is restricted by low bioavailability partly due to Panax notoginseng saponins (PNS) instability and low in vivo absorption."( Pharmacokinetics of Panax notoginseng Saponins in Adhesive and Normal Preparation of Fufang Danshen.
Bai, J; Chen, XN; Du, SY; Li, DQ; Li, PY; Lu, Y; Tian, ZH; Wu, YL; Yu, GY; Zeng, YY; Zhao, MD, 2018
)
0.48
"It was found that the modification with adhesive materials improved PNS bioavailability in Fufang Danshen formula."( Pharmacokinetics of Panax notoginseng Saponins in Adhesive and Normal Preparation of Fufang Danshen.
Bai, J; Chen, XN; Du, SY; Li, DQ; Li, PY; Lu, Y; Tian, ZH; Wu, YL; Yu, GY; Zeng, YY; Zhao, MD, 2018
)
0.48
" From the prospective of drug development, we discussed the limitations of the present investigations and proposed our ideas to increase permeability and bioavailability of Rg1."( Ginsenoside Rg1 in neurological diseases: From bench to bedside.
Chen, LX; Cheng, P; Hu, JM; Wang, JJ; Yang, SJ; Zhu, GQ, 2023
)
2.35
"Compared with traditional drugs, nanomaterial drugs have the benefits of improving the solubility, bioavailability, and absorption rate of insoluble drugs."( Ginsenoside Rg1 Nanoparticles Induce Demethylation of H3K27me3 in VEGF-A and Jagged 1 Promoter Regions to Activate Angiogenesis After Ischemic Stroke.
Cai, H; Lu, L; Shang, W; Shen, J; Wang, D; Xu, Z; Yang, F; Zhao, X; Zhao, Z, 2022
)
2.16
"The pharmacokinetic parameters of bioactive components were significantly changed for better bioavailability and absorption, longer lasting time elimination, which were beneficial for enhancing therapeutic efficacy in the P-QSP group."( Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS.
Chen, L; Chen, Y; Jiang, Y; Kong, M; Li, J; Wang, Q; Wei, N; Xu, L; Yuan, C, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" A rapid, simple and accurate method has been established for determination of ginsenoside-Rg(1) in Shenmai injection and human plasma using LC-ESI-MS/MS, and to study the pharmacokinetics of Rg(1) in ten healthy volunteers after intravenous single dosing of 60 mL of Shenmai injection."( Determination of ginsenoside-Rg(1) in human plasma and its application to pharmacokinetic studies following intravenous administration of 'Shenmai' injection.
Liu, YM; Wu, ZF; Xu, SJ; Yang, L; Zeng, X, 2009
)
0.35
" Both compounds significantly enhanced glucose uptake in 3T3-L1 adipocytes in a dose-response manner, which is correlated with increased GLUT4 translocation from intracellular vesicles to the plasma membrane in adipocytes."( Effect and mechanism of ginsenosides CK and Rg1 on stimulation of glucose uptake in 3T3-L1 adipocytes.
Chang, TC; Chang, WL; Huang, SF; Huang, YC; Lin, CY; Lin, HC, 2010
)
0.36
" The unmodeled control group was given an equal dosage of normal saline by the same route."( [Effect and mechanism of ginsenoside Rg1 as an alcoholic hepatitis treatment in a rat model].
Huang, W; Liu, C; Liu, S; Shi, Z; Tang, J; Xin, X; Zhao, J, 2015
)
0.72
" dosing and oral administration of Rg1 was further examined, which clearly showed that mono-oxygenated metabolites of Rg1 were major circulating metabolites at the early stage after dosing."( Characterization of oxygenated metabolites of ginsenoside Rg1 in plasma and urine of rat.
Bai, LP; Chen, CY; Hu, M; Jiang, ZH; Liu, L; Ma, J; Tong, TT; Wang, JR; Yau, LF, 2016
)
0.69
" Seven days after STZ injection, 10 rats were randomly selected as diabetic model (DM) controls, 45 eligible diabetic rats were randomized to three treatment groups and administered ginsenoside Rg1 in a dosage of 10, 15 or 20 mg/kg/day, respectively."( Ginsenoside Rg1 ameliorates diabetic cardiomyopathy by inhibiting endoplasmic reticulum stress-induced apoptosis in a streptozotocin-induced diabetes rat model.
Gu, J; Liu, Q; Wu, S; Yang, Y; Yu, H; Zhen, J, 2016
)
2.07
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
pro-angiogenic agentAny compound that promotes the growth of new blood vessels from pre-existing vessels.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
12beta-hydroxy steroid
beta-D-glucosideAny D-glucoside in which the anomeric centre has beta-configuration.
tetracyclic triterpenoidAny triterpenoid consisting of a tetracyclic skeleton.
ginsenosideTriterpenoid saponins with a dammarane-like skeleton originally isolated from ginseng (Panax) species. Use of the term has been extended to include semi-synthetic derivatives.
3beta-hydroxy-4,4-dimethylsteroidAny 3beta-hydroxy steroid which is substituted by two methyl groups at position 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
ginsenosides biosynthesis225
ginsenosides biosynthesis1032

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1674947Binding affinity to rabbit CK-MM at 20 uM2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
AID595753Cytotoxicity against human A549 cells assessed as growth inhibition after 3 days by sulforhodamine B assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Bioactive constituents from the roots of Panax japonicus var. major and development of a LC-MS/MS method for distinguishing between natural and artifactual compounds.
AID595752Cytotoxicity against human DU145 cells assessed as growth inhibition after 3 days by sulforhodamine B assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Bioactive constituents from the roots of Panax japonicus var. major and development of a LC-MS/MS method for distinguishing between natural and artifactual compounds.
AID334335Induction of morphological transformation of rat ASK cells into astrocytes at 100 ug/ml after 1 hr by light microscopy
AID595749Inhibition of fMLP/CB-stimulated superoxide anion generation in human neutrophils at 30 uM relative to control2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Bioactive constituents from the roots of Panax japonicus var. major and development of a LC-MS/MS method for distinguishing between natural and artifactual compounds.
AID1210049Cytoprotective activity in neonatal HDF assessed as reduction of BaP-induced cell death at 10 uM after 24 hrs by MTT assay2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Cytoprotective effect of 20S-Rg3 on benzo[a]pyrene-induced DNA damage.
AID1674948Activation of rabbit CK-MM assessed as increase in enzyme activity at 5 to 80 uM2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
AID359683Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 100 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID1210052Cytoprotective activity in neonatal HDF assessed as reduction of BaP-induced tail moment at 10 uM after 24 hrs by comet assay2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Cytoprotective effect of 20S-Rg3 on benzo[a]pyrene-induced DNA damage.
AID397814Induction of neurite outgrowth in human SK-N-SH cells at 100 uM after 5 days relative to control2002Journal of natural products, Sep, Volume: 65, Issue:9
Dammarane-type Saponins from Panax japonicus and their neurite outgrowth activity in SK-N-SH cells.
AID359682Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID337110Hepatoprotective activity against D-galactosamine/LPS-induced liver injury in ddY mouse assessed as inhibition of serum aspartate transaminase level at 100 mg/kg, ip administered 1 hr before D-galactosamine/LPS challenge by Reitman-Frankel method2003Journal of natural products, Jul, Volume: 66, Issue:7
Structures of new dammarane-type Triterpene Saponins from the flower buds of Panax notoginseng and hepatoprotective effects of principal Ginseng Saponins.
AID359495Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 200 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID359484Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 200 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID359494Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 100 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID359488Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID359493Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID337107Hepatoprotective activity against D-galactosamine/LPS-induced liver injury in ddY mouse assessed as inhibition of serum alanine transaminase level at 100 mg/kg, ip administered 1 hr before D-galactosamine/LPS challenge by Reitman-Frankel method2003Journal of natural products, Jul, Volume: 66, Issue:7
Structures of new dammarane-type Triterpene Saponins from the flower buds of Panax notoginseng and hepatoprotective effects of principal Ginseng Saponins.
AID1210050Cytotoxicity against neonatal HDF assessed as cell viability at 10 uM after 24 hrs by MTT assay relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Cytoprotective effect of 20S-Rg3 on benzo[a]pyrene-induced DNA damage.
AID359490Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 200 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID595754Cytotoxicity against human HCT8 cells assessed as growth inhibition after 3 days by sulforhodamine B assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Bioactive constituents from the roots of Panax japonicus var. major and development of a LC-MS/MS method for distinguishing between natural and artifactual compounds.
AID1210051Cytoprotective activity in neonatal HDF assessed as reduction of BaP-induced DNA strand breakage by measuring tunnel positive cells at 10 uM after 24 hrs (Rvb = 15.96%)2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Cytoprotective effect of 20S-Rg3 on benzo[a]pyrene-induced DNA damage.
AID359487Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID595750Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release at 30 uM using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins relative to control2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Bioactive constituents from the roots of Panax japonicus var. major and development of a LC-MS/MS method for distinguishing between natural and artifactual compounds.
AID595751Cytotoxicity against human KB cells assessed as growth inhibition after 3 days by sulforhodamine B assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Bioactive constituents from the roots of Panax japonicus var. major and development of a LC-MS/MS method for distinguishing between natural and artifactual compounds.
AID359489Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 100 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (755)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (2.12)18.7374
1990's43 (5.70)18.2507
2000's172 (22.78)29.6817
2010's387 (51.26)24.3611
2020's137 (18.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.30 (24.57)
Research Supply Index6.65 (2.92)
Research Growth Index5.30 (4.65)
Search Engine Demand Index59.94 (26.88)
Search Engine Supply Index3.96 (0.95)

This Compound (25.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (0.52%)5.53%
Reviews25 (3.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other738 (96.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]